Daily Archives: April 6, 2020

Non-alcoholic fatty liver is a risk factor for liver cancer

April 6th, 2020 Liver cancer

Nonalcoholic fatty liver disease (NAFLD) is a very common disease. To better understand the link between NAFLD and hepatocellular carcinoma (HCC) risk, researchers at Baylor College of Medicine conducted a large Retrospective study published in .... Read More

DNA testing can detect early liver cancer – Mayo clinic study

April 6th, 2020 Liver cancer

Researchers at the Mayo Clinic in the United States reported at the 2018 Digestive Disease Week meeting that they have developed a DNA blood test that can correctly identify 95% of common liver cancer cases.At present, ultrasound and alpha-fetop.... Read More

Lovastinib for the treatment of first-line hepatocellular carcinoma

April 6th, 2020 Liver cancer

Based on data from the REFLECT phase III trial, the US Food and Drug Administration (FDA) approved Lenvima as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The test was published in The Lancet in Febru.... Read More

A new drug in the treatment of liver cancer

April 6th, 2020 Drugs, Liver cancer

A research team at the Cancer Research Institute (CSI) of the National University of Singapore has developed a novel peptide drug called FFW that may prevent the development of hepatocellular carcinoma (HCC) or primary liver cancer . This l.... Read More

Roche PD-1 inhibitor liver cancer combination therapy was recognized by the FDA as a breakthrough therapy

April 6th, 2020 Liver cancer

The Swiss Roche Group announced yesterday that TECENTRIQ® (atezolizumab) in combination with Avastin® (bevacizumab) has been approved by the US Food and Drug Administration (FDA) for breakthrough therapy for initial (first-line) treatment of a.... Read More

Cabozantinib prolongs progression-free survival for advanced liver cancer

April 6th, 2020 Liver cancer

According to a study published in the New England Journal of Medicine published on July 5, Cabozantinib's overall and progression-free survival in patients with advanced hepatocellular carcinoma was significantly better than the placebo group.Dr.... Read More

Benefits of Ramucirumab for patients with high AFP liver cancer

April 6th, 2020 Liver cancer

Liver cancerLiver cancer is a typical vascular-rich tumor, and tumor blood vessels play a very important role in the development of liver cancer. Therefore, the current targeted therapy of liver cancer is carried out around anti-angiogenesis. An.... Read More

Drug for thrombocytopenia

April 6th, 2020 Drugs

Dova Pharmaceuticals announced that the US FDA approved its subsidiary AkaRx's new drug Doptelet (avatrombopag) tablets for the treatment of low platelet counts (thrombocytopenia) in adults with chronic liver disease (CLD) who are scheduled to u.... Read More

Proton therapy for liver cancer is part of guidelines

April 6th, 2020 Liver cancer

UN NCCN guidelines The US NCCN Clinical Practice Guidelines: Hepatobiliary Tumor (2018.V1) was updated on February 15, 2018. The latest version of the guideline uses proton therapy as one of the standard treatments for head and neck cancer. Nat.... Read More

New method to detect liver cancer biomarkers

April 6th, 2020 Liver cancer

Because liver cancer has many types, strong inheritance, and easy recurrence, identifying biomarkers that can predict disease progression is a key goal in fighting liver cancer.Recently, researchers have developed a method to identify the most c.... Read More